SDS-OmiProbe SIGNED
Revolutionary opto-biological methodology for aggressive HER2 cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SDS-OmiProbe project word cloud
Explore the words cloud of the SDS-OmiProbe project. It provides you a very rough idea of what is the project "SDS-OmiProbe" about.
Project "SDS-OmiProbe" data sheet
The following table provides information about the project.
| Coordinator |
SDS OPTIC SPOLKA AKCYJNA
Organization address contact info |
| Coordinator Country | Poland [PL] |
| Project website | https://sdsoptic.pl/ |
| Total cost | 3˙985˙000 € |
| EC max contribution | 3˙985˙000 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-12-01 to 2021-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | SDS OPTIC SPOLKA AKCYJNA | PL (LUBLIN) | coordinator | 3˙985˙000.00 |
Map
Project objective
According to World Health Organization, cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year. Breast cancer is the most common cancer among women, and is considered the second most common cancer overall. Each year about 1.7 million new cases are diagnosed worldwide and over 500,000 women die from the disease.
Current diagnosis methods of cancers fail to deliver objective results. Diagnosis require extracting tissue samples via invasive and expensive biopsy, followed by laboratory analysis, which are subject to significant levels of discordance.
SDS Optic presents a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. SDS-OmiProbe detects presence and measures concentration levels of the HER2 cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs.
There is compelling evidence that our novel SDS-OmiProbe is addressing a rapid growth trend in a high volume market. Based on Transparency Market Research Report the OmiProbe target market of HER2- biomarker tests is projected to be worth $4.6 billion, with 7.5 million HER2 marker tests performed annually worldwide.
In order to close the striking gap in the landscape of currently available cancer diagnostic and targeted therapy tools, and to realize the significant global business opportunity the objective of this project is optimization of the SDS-OmiProbe device, followed by realization of independent clinical trials and dissemination of the results.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SDS-OMIPROBE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SDS-OMIPROBE" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
RESHAPE (2019)
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More